Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2010 - 2026)

Nektar Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $151000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 64.55% year-over-year to $151000.0 in Q1 2026; TTM through Mar 2026 was $685000.0, a 63.37% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, down 76.63% from the prior year.
• Depreciation & Amortization (CF) fell to $151000.0 in Q1 2026 per NKTR's latest filing, from $190000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.7 million in Q1 2022 and bottomed at $151000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $1.6 million (2024), against an average of $1.5 million.
• Across the five-year window, Depreciation & Amortization (CF) grew 5.28% in 2022 and plunged 79.9% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $3.2 million in 2022, then slumped by 48.08% to $1.7 million in 2023, then plunged by 79.9% to $332000.0 in 2024, then sank by 42.77% to $190000.0 in 2025, then dropped by 20.53% to $151000.0 in 2026.
• Per Business Quant, the three latest NKTR Depreciation & Amortization (CF) figures stand at $151000.0 (Q1 2026), $190000.0 (Q4 2025), and $163000.0 (Q3 2025).